ArrayExpress Uploader0humanHCC78EGFR WTErlotinibHCC78EGFR WTErlotinibHCC78EGFR WTDMSOHCC78EGFR WTDMSONCI-H1648EGFR WTErlotinibNCI-H1648EGFR WTErlotinibNCI-H1648EGFR WTDMSONCI-H1648EGFR WTDMSONCI-H838EGFR WTErlotinibNCI-H838EGFR WTErlotinibNCI-H838EGFR WTDMSONCI-H838EGFR WTDMSONCI-H23EGFR WTErlotinibNCI-H23EGFR WTErlotinibNCI-H23EGFR WTDMSONCI-H23EGFR WTDMSOHCC2935EGFR MutantErlotinibHCC2935EGFR MutantErlotinibHCC2935EGFR MutantDMSOHCC2935EGFR MutantDMSOHCC2279EGFR MutantErlotinibHCC2279EGFR MutantErlotinibHCC2279EGFR MutantDMSOHCC2279EGFR MutantDMSOHCC4006EGFR MutantErlotinibHCC4006EGFR MutantErlotinibHCC4006EGFR MutantDMSOHCC4006EGFR MutantDMSOPC-9EGFR MutantErlotinibPC-9EGFR MutantErlotinibPC-9EGFR MutantDMSOPC-9EGFR MutantDMSO2023arrayexpress_sid4Non-small cell lung cancers (NSCLCs) harboring activating EGFR mutants show dramatic responses to EGFR TKIs, such as erlotinib and...E-GEOD-57156/profile/8773/arrayexpressuploader332celllungnsclcDec.12, 2014Falseexpression-data-from-egfr-wt-or-egfr-mutant-nsclcE-GEOD-57156_A-AFFY-44Expression data from EGFR WT or EGFR mutant NSCLC with or without erlotinibJul.10, 2014Non-small cell lung cancers (NSCLCs) harboring activating EGFR mutants show dramatic responses to EGFR TKIs, such as erlotinib and geffitinib. However, nearly all patients show relapse within 1 year after initial treatment. We used microarrays to detail global gene expression changes in EGFR mutant cells vs. WT cells responding to erlotinib. 4 EGFR mutant and 4 WT NSCLC cells were treated with or without erlotinib for 24 hr, followed by RNA extraction and hybridization on Affymetrix microarrays.http://www.ebi.ac.uk/arrayexpress/experiments/E-GEOD-57156http://www.ebi.ac.uk/arrayexpress/experiments/E-GEOD-57156/samples/